Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Enovis (NYSE: ENOV) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference, with a presentation on Monday, January 12, 2026 at 4:30 p.m. PST (7:30 p.m. EST).
A live audio webcast, accompanying presentation slides, and a replay will be available on the company website under Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction – ENOV
In the Jan 8 session, ENOV gained 4.12%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Leadership appointment | Positive | +3.4% | New Chief Administrative Officer hired to drive strategy and efficiency. |
| Nov 06 | Earnings results | Negative | -9.8% | Q3 2025 results with large non-cash goodwill impairment and GAAP net loss. |
| Oct 24 | Earnings & conferences | Neutral | -0.0% | Announcement of Q3 2025 earnings call and participation in investor conferences. |
| Oct 08 | Asset divestiture | Positive | +4.8% | Completed sale of Dr. Comfort Footcare business for up to $60 million. |
| Sep 08 | Conference timing | Neutral | -0.7% | Time change for presentation at Baird 2025 Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent moves generally aligned with news tone: leadership and portfolio moves saw gains, while results with large goodwill impairment saw a notable decline.
Over the last few months, Enovis reported Q3 2025 results with net sales around $549 million but a large non-cash goodwill impairment, which coincided with a -9.75% move. The company completed the sale of its Dr. Comfort Footcare business for up to $60 million, and that news saw a +4.78% reaction. Leadership and scheduling updates, including a new Chief Administrative Officer and prior conference announcements, produced modest share moves. The current J.P. Morgan conference participation fits into this pattern of ongoing investor engagement.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website (www.enovis.com) at Events and Presentations.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Contact:
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com
